Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments

EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

(2011) Nicolas Mottet et al.   EUROPEAN UROLOGY

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

(2011) James W Denham et al.   LANCET ONCOLOGY

Abiraterone and Increased Survival in Metastatic Prostate Cancer

(2011) Johann S. de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predictors of Androgen Deprivation Therapy Efficacy Combined With Prostatic Irradiation: The Central Role of Tumor Stage and Radiation Dose

(2010) Scott Williams et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

7007 Three years of adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: Results at 10 years of EORTC trial 22863

(2009) M. Bolla et al.   EJC SUPPLEMENTS

Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics

(2009) Bertrand Tombal et al.   EUROPEAN UROLOGY

Is Biochemical Response More Important Than Duration of Neoadjuvant Hormone Therapy Before Radiotherapy for Clinically Localized Prostate Cancer? An Analysis of the 3- Versus 8-Month Randomized Trial

(2009) Abraham Alexander et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Duration of Androgen Suppression in the Treatment of Prostate Cancer

(2009) Michel Bolla et al.   NEW ENGLAND JOURNAL OF MEDICINE

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

(2008) Laurence Klotz et al.   BJU INTERNATIONAL

Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer

(2008) Hendrik Van Poppel et al.   EUROPEAN UROLOGY

Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610

(2008) Mack Roach et al.   JOURNAL OF CLINICAL ONCOLOGY

Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer

(2008) Eric M. Horwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America

(2008) Marc Gittelman et al.   JOURNAL OF UROLOGY

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

(2008) Anders Widmark et al.   LANCET

Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?

(2008) Hendrik van Poppel et al.   UROLOGY